Free delivery over $100 Learn more

30 days return period Learn more
SKU: 0302ATC

HEL Human Peripheral Blood Immune Cells

Tumor Cell Lines > Leukemia Cell Lines

Product Type: Human Leukemia Cell Lines

Species: Human

Cell Type: Immune Cells

Source Organ: Blood

$1,249.00
Size

Care information

Display general product information or specific product information using metafields.

Delivery and Shipping

Add some general information about your delivery and shipping policies.

Cell Name: HEL

HEL Cell Line is from human; Tissue: hemo-lymphocytic; Morphology: lymphocyte-like; Profile: leukemia, erythroid.

  • Description
    HEL is a human erythroleukemia cell line established from the peripheral blood of a 30-year-old Caucasian male who developed therapy-related erythroleukemia following relapse after Hodgkin’s lymphoma treatment. These cells exhibit lymphoblastoid-like morphology and grow predominantly in suspension, although a subset may demonstrates semi-adherent properties in culture. HEL has a doubling time of approximately 24 – 36 hours. HEL harbors the JAK2 V617F mutation, commonly associated with myeloproliferative neoplasms. It expresses a range of surface antigens, including CD13, CD33, CD41a, CD71, and CD235a, as well as HLA A3, Aw32 and Bw35. In vivo studies confirm its tumorigenic potential, with subcutaneous or intravenous inoculation in immunodeficient mice. HEL serves as a model for studying erythroid differentiation and globin gene regulation, and leukemogenesis.
  • Product Name
    HEL
  • Product Type
    Human Leukemia Cell Lines
  • Species
    Human
  • Cell Type
    Lymphocyte-like
  • Source Organ
    Peripheral Blood
  • Product Type
    Human Leukemia Cell Lines
  • Growth Conditions
    37 °C, 5% CO2
  • Application
    HEL cells serve as a versatile model for investigating the mechanisms governing erythroid lineage differentiation and the regulation of globin gene expression. They serve as a valuable tool for assessing potential therapeutic interventions targeting erythroleukemia, including strategies aimed at inducing apoptosis or modulating JAK-STAT signaling. Given the presence of the JAK2 V617F mutation, HEL cells contribute significantly in dissecting the molecular pathways implicated in myeloproliferative neoplasms, aiding in the development of targeted therapies. Furthermore, it provide a robust model for drug screening, signal transduction studies, and understanding the hematopoietic effects of various pharmacologic agents.
  • Size/Quantity
    1 vial
  • Recommended Medium And Supplement

    RPMI 1640 + 10% FBS
  • Shipping Conditions
    Dry Ice
  • Storage
    Liquid Nitrogen
  • Biosafety Level
    1

Payment & Security

Payment methods

    Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

    • Visit our support center

      Expert help & advice

    • Check your order status

      Updates & tracking

    • Returns & exchanges

      All you need to know

    • Price-match guarantee

      Our promise to you